ST明誠(600136.SH):擬對聯影創藝增資2000萬元
格隆匯8月1日丨ST明誠(600136.SH)公佈,聯影創藝為公司於2024年2月28日設立的全資子公司,註冊資本1,000萬元(公司已分別於2024年3月1日、6月5日完成實繳)。為進一步擴大其經營規模,提高其資金實力和市場競爭力,公司擬以自有資金對聯影創藝增資2,000萬元。增資完成後,聯影創藝的註冊資本將由人民幣1,000萬元增至3,000萬元,仍為公司全資子公司。
聯影創藝主營業務為文藝演出、劇場演藝、影視製作與影視項目投資等,其中文藝演出、劇場演藝業務為聯影創藝在公司原有業務基礎上逐步拓展的新業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.